T issue plasminogen activator (tPA) has been used as a thrombolytic agent for many years based on its high fibrin specificity, which contributes to its safety in thrombolytic therapy. 1, 2 Despite the favorable results associated with tPA treatments, its use is limited to the first 4.5 hours after the onset of event, and the dosage is strictly restricted in stroke treatment to avoid brain injury and bleeding. Thus, novel thrombolytic agents providing more safe and effective thrombolysis are desired. 3 Fibrinolytic system dissolves unnecessary and aged thrombi, as well as newly generated and overabundant thrombi that exceed current hemostatic requirements. Similar to the coagulation system, the fibrinolytic system is strictly regulated 4 to help maintain blood flow to the periphery. To achieve this complicated task, several distinct regulatory systems operate at the plasminogen activation and fibrin degradation levels (Figure 1 ). At the level of plasminogen activation, plasminogen activator inhibitor type 1 (PAI-1) plays the most important role by regulating the activity of tPA, 5, 6 which is the main PA in the vasculature and the most frequently used PA for thrombolytic therapy.
Alpha 2-antiplasmin (α2AP) and thrombin activatable fibrinolysis inhibitor (TAFI) play major roles in fibrinolysis. 4 Plasmin activity is inhibited by α2AP forming a highmolecular-weight complex. TAFI, after activation by thrombin or more effectively by thrombomodulin-bound thrombin, acts as a carboxypeptidase to cleave C-terminal lysine residues from proteins. 7 Because the C-terminal lysine residues of partially digested fibrin or cell surface-bound proteins 8 play essential roles in the induction and amplification of fibrinolysis, as discussed below, their removal by activated TAFI naturally suppresses fibrinolysis.
During thrombolytic treatment, these regulatory systems must be overcome at the thrombus site to achieve effective thrombolysis. However, these systems must also be at least partially maintained in the systemic circulation to avoid unnecessary bleeding. Many efforts have been made to develop novel agents targeting these regulatory systems. 3 High plasma levels of PAI-1 are associated with risk of thrombosis, and low plasma levels can result in life-threatening bleeding. 5 In this context, many drugs have been developed to target PAI-1 as an important regulator of fibrinolysis. PAI-1 inhibitors appear to be more promising as antithrombotic drugs than thrombolytic agents because PAI-1 also functions to enlarge the size of growing thrombi under shear stress. 9 When tPA is used as a thrombolytic agent, the dosage must be high enough to overcome PAI-1 activity in the circulation and permit the activity of tPA, which indicates that the safety and efficacy of thrombolytic therapy depends mainly on regulators other than PAI-1.
One of the non-PAI-1 regulators is α2AP, which is a member of the serine protease inhibitor superfamily and specifically inhibits plasmin activity by forming a stoichiometThrombolytic Therapy Targeting Alpha 2-Antiplasmin ric high-molecular-weight complex. 1, 10 This regulator has a long C-terminal sequence with a terminal lysine residue, which functions as a secondary binding site for free circulating plasmin and facilitates plasmin inactivation. The binding is mediated by the lysine binding site, which is located in the kringle domains on plasmin. However, when plasmin is bound to fibrin through the lysine binding site, α2AP can no longer bind plasmin, and plasmin remains active on the fibrin surface. In addition, plasminogen binds to the C-terminal lysine residues of fibrin through the lysine binding site, which alters the conformation of plasminogen and makes it more susceptible to activation by tPA. 8 Furthermore, the binding increases the opportunity for plasminogen to react with fibrin-bound tPA and facilitates the generation of plasmin on the fibrin surface. This sequence is considered one of the mechanisms underlying the quick dissolution of unnecessary and excessive thrombi. In contrast, the disruption of this mechanism through the removal of C-terminal lysine residues by activated TAFI 7 is considered one of the mechanisms that protect hemostatic thrombi from early dissolution.
Immature hemostatic thrombi can also be protected from early dissolution by α2AP. This protection occurs through the cross-linking of α2AP to fibrin by activated coagulation factor XIII. 11 The cross-linking is more effective when native α2AP are cleaved into truncated forms at Pro12-Asn13 by an antiplasmin-cleaving enzyme. 12 The importance of this cross-linkage in the protection of hemostatic thrombi is clearly demonstrated by the unique "secondary" hemorrhage observed after trauma or surgery in patients who are deficient in either α2AP or FXIII. 10 In this issue of Circulation, Singh et al 13 report their attempt to achieve effective thrombolysis by reducing α2AP activity through the use of a neutralizing antibody targeting α2AP (α2AP-I). This antibody is described to bind both circulating and fibrin-bound α2AP, and its binding effectively neutralizes the specific activity of α2AP.
In an in vivo model of pulmonary emboli, α2AP-I alone initiated spontaneous thrombolysis and successfully potentiated tPA-mediated thrombolysis. Using a humanized α2AP mouse model, in which α2AP-deficient mice were pretreated using human α2AP, Singh et al 13 also demonstrated that pulmonary emboli made of human whole blood were efficiently dissolved by a combination of tPA and α2AP-I, which produced less fibrinogen degradation and bleeding compared with the equivalent amount of tPA alone. Because the resistance of thrombi to thrombolysis is largely influenced by the amount of active α2AP contained in the thrombi (as demonstrated using an α2AP-deficient patient's plasma 10 and an animal model 14 ), the results reported by Singh et al 13 are logical if we assume that α2AP-I might have effectively reduced the amounts of active α2AP in the thrombi. The binding of α2AP-I might also have dissociated cross-linked α2AP from fibrin because the binding is reported to be reversible. 15 The precise molecular mechanism underlying how these large molecules (α2AP-Is) effectively inactivate fibrin-bound α2AP should be clarified to establish the efficacy of α2AP-I as a thrombolytic agent.
After the injection of α2AP-I in the Singh et al 13 study, α2AP activity in the plasma quickly declined, which suggests that α2AP was successfully neutralized by the antibodies in the plasma, although the antigen levels did not change in the circulation. Because a similar decrease in the plasma activity of α2AP is observed during thrombolytic therapy and is associated with better recanalization of the occluded vessels, 16 the decrease in the plasma activity of α2AP may have contributed to the effective thrombolysis. However, consumption of α2AP in the circulation is commonly associated with more severe fibrinogen degradation and bleeding tendency during ordinary thrombolytic therapy. In contrast, Singh et al 13 used α2AP-I alone or α2AP-I combined with low-dose tPA and observed significantly lower fibrinogen degradation and bleeding tendency in both instances compared with treatment using an equivalent dose of tPA. Thus, Singh et al 13 
Figure 1. Regulatory mechanisms of fibrinolysis.
Mechanisms that contribute to the quick lysis of excess and unnecessary thrombi (upper right), and mechanisms that contribute to protecting hemostatic thrombi from early dissolution (lower) and inhibit fibrinolysis in plasma (upper left). The α2AP-I antibody enhances fibrinolysis by decreasing the amount of active α2AP in the thrombi. α2AP indicates alpha 2-antiplasmin; α2AP-I, neutralizing antibody targeting α2AP; PAI-1, plasminogen activator inhibitor 1; TAFI, thrombin activatable fibrinolysis inhibitor; TM, thrombomodulin; and tPA, tissue plasminogen activator. speculated that this result was attributable to the substitutional participation of other plasmin inhibitors, including α2-macroglobulin, in the inhibition of plasmin activity in the plasma. However, the ability of α2-macroglobulin to inhibit plasmin is much lower than that of α2AP, 10 and a similar supplemental role for α2-macroglobulin is expected, even during ordinary thrombolytic therapy.
A fundamental difference between tPA and α2AP-I is that the latter does not directly activate plasminogen to generate plasmin. Thus, the consumption of α2AP by α2AP-I in the circulation may not evoke the degradation of coagulation factors, including fibrinogen, unless a large amount of plasmin is generated at the thrombus site. Because a lesser degree of plasmin generation in the circulation is essential for safe thrombolytic therapy, the underlying mechanism should be thoroughly clarified before α2AP-I can be used clinically.
The quick dissolution of thrombi through safe and effective thrombolytic therapy remains desirable for individuals with thrombotic disorders, especially stroke and pulmonary embolism. 17 Thus, regulators of fibrinolysis, including PAI-1, α2AP, and TAFI, are good targets for the development of novel thrombolytic agents that can be used alone or as an adjuvant therapy. 3 Therefore, it is critically important to thoroughly understand how these regulators spatiotemporally control fibrinolysis under both physiological and pathological conditions, and how new thrombolytic agents modify the entire control system.
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